These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31081592)

  • 1. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.
    Brown E; Rajeev SP; Cuthbertson DJ; Wilding JPH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():9-18. PubMed ID: 31081592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.
    Zelniker TA; Braunwald E
    J Am Coll Cardiol; 2018 Oct; 72(15):1845-1855. PubMed ID: 30075873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering.
    Ceylan AF; Ren SY
    Curr Drug Targets; 2018; 19(9):1045-1050. PubMed ID: 29673309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibition and kidney protection.
    Nespoux J; Vallon V
    Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal physiology of glucose handling and therapeutic implications.
    Cherney DZ; Kanbay M; Lovshin JA
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i3-i12. PubMed ID: 32003835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More CREDENCE for SGLT2 Inhibition.
    Verma S; Bhatt DL
    Circulation; 2019 Oct; 140(18):1448-1450. PubMed ID: 31181959
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
    Pandey J; Tamrakar AK
    Expert Opin Ther Pat; 2019 May; 29(5):369-384. PubMed ID: 31026402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sodium-glucose cotransporter inhibitors on cardiorenal and metabolic systems: Latest perspectives from the outcome trials.
    Lim S
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():5-8. PubMed ID: 31081588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of type 2 sodium glucose co-transporters--a new strategy for diabetes treatment.
    Bołdys A; Okopień B
    Pharmacol Rep; 2009; 61(5):778-84. PubMed ID: 19904000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
    Zelniker TA; Braunwald E
    J Am Coll Cardiol; 2020 Feb; 75(4):435-447. PubMed ID: 32000956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.